Bio-Rad has been challenged by tough end-market conditions in life sciences tools, but the outlook for 2025 is better. The company's cautious approach has led to lackluster sales growth and margin ...
HERCULES, Calif., July 31, 2025--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the ...
Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, today announced that MicroVal, the international certification organization for the validation ...
Longleaf Partners, managed by Southeastern Asset Management, released its “Partners Fund” third-quarter 2025 investor letter. The letter can be downloaded here. The fund returned -0.33% in the third ...
I rate Bio-Rad (BIO) with a buy rating. I start by mentioning that the low growth perspective is the negative aspect. For 2025, the company expects a 0.25% growth rate for its revenues, which might ...
HERCULES, Calif., July 07, 2025--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the ...
Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, today announced the launch of its first ultrasensitive multiplexed digital PCR assay, the ddPLEX ...
Bio-Rad Names Anette Engelhardt Executive Vice President and President of Clinical Diagnostics Group
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Anette Engelhardt ...
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, announced today that it has reached an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback